Early Luteal Phase Hormone Changes After Triggering Ovulation in a Modified Natural Cycle
Official title: Evolution of Luteal Progesteronemia in a Modified Natural Cycle (Ovulation Triggered by hCG): Pilot Study
Run by University Hospital, Montpellier · NCT07028710 · Data updated 2026-11-12
This pilot test will measure how progesterone rises after hCG-triggered ovulation in women using a modified natural cycle for embryo transfer.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Status | Recruiting |
| Started | January 12, 2026 |
| Main results expected | June 15, 2028 |
| Study ends | June 15, 2030 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07028710 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women preparing for frozen embryo transfer, with at least one follicle ≥14 mm and endometrium ≥6 mm, and LH and progesterone levels meeting specified criteria.
✕Probably not a fit
Patients with contraindications to repeated blood draws or who are not fluent in French may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this single-arm pilot study, 40 women preparing for a frozen embryo transfer will have blood tests over six days to track progesterone, LH, and related hormones after ovulation is triggered with hCG. The goal is to see how hCG timing affects the luteal phase and potential implantation. Participants must meet hormone and follicle criteria and be undergoing standard care with recombinant hCG. The study uses routine blood sampling and imposes exclusions to protect those at risk or unable to consent.
Why it matters
Potential benefit: If successful, the findings could clarify luteal phase timing after hCG and help optimize embryo transfer timing.
How similar studies have gone: Previous research has explored luteal phase hormones in natural or modified cycles, but this specific timing after hCG in a modified natural cycle is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 1 follicle of 14 mm or more * Endometrium of 6 mm or more * Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng/mL * For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care). Exclusion Criteria: * Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period. * Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion. * Patient who has not given written consent to participate in the study. * Patient not fluent in French. * Patient under guardianship, curators or without social security coverage. * Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .
Where it's running
-
Hôpital Arnaud de Villeneuve
Montpellier, France Recruiting
Study contacts
- Principal investigator: Noémie RANISAVLJEVIC, Investigator Coordinator — CHU de Montpellier
- Study coordinator: Noémie RANISAVLJEVIC, Senior Lecturer - Hospital Pra
- Email: n-ranisavljevic@chu-montpellier.fr
- Phone: 04 67 33 64 81
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Islet re-transplantation after prior graft failure in adults with type 1 diabetes
This study looks at whether giving another islet transplant after a prior failed graft helps adults with type 1 diabetes who have severe swings in blood sugar.
-
Tissue models of systemic sclerosis using patient-derived iPSCs
Researchers will create iPSC lines from people with systemic sclerosis, their healthy relatives, and test them across several cell types to see how the disease affects tissues in the lab.
-
L-dopa treatment for a CTNNB1-related neurodevelopmental disorder in children
This study tests whether L-dopa can help children with a CTNNB1-related neurodevelopmental disorder who have dystonia.
-
Exploratory look at brain blood flow and metabolism before and after removing unruptured AVMs
This study tests brain perfusion and metabolism with PET imaging and neuropsychological tests in adults before and six months after surgical treatment for unruptured brain AVMs.
-
Immun4Cure Cohort of Autoimmune Diseases
A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.
-
Comparing supra-annular versus intra-annular self-expanding aortic valves in routine TAVR practice
This project will try to see if the supra‑annular Evolut valve or the intra‑annular Navitor valve gives better one‑month procedural success and six‑month clinical and echocardiographic results for patients receiving TAVR with self‑expanding devices.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.